Immix High Response Rate in Multiple Myeloma

 

• 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy
• 98% overall response rate observed in relapsed/refractory multiple myeloma patients without extra-medullary disease
• Updated results will be communicated at the presentation time December 11, 2023

https://www.globenewswire.com/news-release/2023/11/06/2774141/0/en/Immix-Biopharma-Presents-NXC-201-Data-at-65th-American-Society-of-Hematology-ASH-Annual-Meeting-in-63-Relapsed-Refractory-Multiple-Myeloma-Patients.html